Neurocrine Biosciences (NBIX) vs Teva Pharmaceutical Industries (TEVA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Teva Pharmaceutical Industries (TEVA) has outperformed Neurocrine Biosciences (NBIX) over the past year, gaining 94.2% versus a gain of 1.6%. Over five years, TEVA leads with a +305.5% price change compared with +35.1% for NBIX. Teva Pharmaceutical Industries is the larger company by market cap ($45.78 billion vs $14.36 billion), about 3.2 times the size, while Neurocrine Biosciences is growing revenue faster (+21.4% vs +4.3%).
On valuation, Neurocrine Biosciences trades at a lower forward P/E (11.9x vs 12.7x for Teva Pharmaceutical Industries). Neurocrine Biosciences converts more of its revenue into profit, with a net margin of 16.7% versus 8.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NBIX | TEVA |
|---|---|---|
| Share price | $141.25 | $39.25 |
| Market cap | $14.36B | $45.78B |
| 1-day change | -1.55% | +0.18% |
| YTD return | -0.41% | +25.76% |
| 1-year return | +1.56% | +94.21% |
| 5-year return | +35.12% | +305.48% |
| P/E ratio (TTM) | 20.71 | 65.42 |
| Forward P/E | 11.89 | 12.70 |
| EPS (TTM) | $6.82 | $0.60 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.86B | $17.26B |
| Revenue growth (YoY) | +21.45% | +4.32% |
| Net income (latest FY) | $478.60M | $1.41B |
| Gross margin | 98.18% | 51.79% |
| Operating margin | 21.64% | 12.50% |
| Net margin | 16.73% | 8.17% |
| 52-week high | $186.12 | $40.79 |
| 52-week low | $122.14 | $18.83 |
| Distance from 52-week high | -24.11% | -3.78% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +46.75% | +15.41% |
| Average volume | 1.30M | 5.29M |
| Shares outstanding | 101.65M | 1.17B |
| Employees | 2,500 | 31,173 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Teva Pharmaceutical Industries is about 3.2 times larger than Neurocrine Biosciences by market value ($45.78B vs $14.36B).
- TEVA has outperformed NBIX by 92.7 percentage points over the past year.
- Teva Pharmaceutical Industries trades at a higher earnings multiple (65.4x vs 20.7x trailing P/E).
- Neurocrine Biosciences is more profitable, keeping 16.7 cents of every revenue dollar as net income versus 8.2 cents for Teva Pharmaceutical Industries.
- Neurocrine Biosciences grew revenue faster in its latest fiscal year (+21.45% vs +4.32%).
About Neurocrine Biosciences
NBIX stock →Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 2,500 employees
About Teva Pharmaceutical Industries
TEVA stock →Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.
Health Care · Biotechnology: Pharmaceutical Preparations · 31,173 employees
NBIX vs TEVA FAQ
Which is bigger, Neurocrine Biosciences or Teva Pharmaceutical Industries?
Teva Pharmaceutical Industries (TEVA) is larger, with a market capitalization of $45.78B compared with $14.36B for Neurocrine Biosciences (NBIX).
Which stock has performed better over the past year, NBIX or TEVA?
TEVA returned +94.21% over the past 12 months, compared with +1.56% for NBIX (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, NBIX or TEVA?
NBIX has the lower trailing P/E at 20.7, versus 65.4 for TEVA. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Neurocrine Biosciences and Teva Pharmaceutical Industries in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Neurocrine Biosciences and Biotechnology: Pharmaceutical Preparations for Teva Pharmaceutical Industries.